Distribution and Drug Resistance of <i>Acinetobacter baumannii</i> Isolated from Inpatients in Ruijin Hospital from 2008 to 2012_West China Medical Journal

Authors：

 XUGui-ting , MIChen-rong , LIWen-hui , ZHANGYi-bo , GONGZheng-feng , NIYu-xing ,  WANGQun

Department of Nosocomial Infection Management, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, P. R. China;

Corresponding?author：

WANGQun, Email: wangqun83953@126.com

Keywords：

Acinetobacter baumannii; Clinical distribution; Drug resistance; Antimicrobial agents

DOI：

10.7507/1002-0179.20140125

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To study the clinical distribution and the change of drug resistance of Acinetobacter baumannii from different inpatient specimens sources during 2008 to 2012, and to provide guidance for rational use of antibiotics. Methods The identification of Acinetobacter baumannii was conducted by VITEK-2 based on clinical and laboratory standards institute (CLSI) guideline between January 2008 and December 2012. The susceptibility of antibiotics was determined by K-B test, and data analysis was conducted by Excel and SAS. Results A total of 3 139 stains of Acinetobacter baumannii were isolated from 2013 patients during this period. The Acinetobacter baumannii was mainly obtained from the Burn ward, Intensive Care Unit ward and Thoracic ward. Sputum was the most specimens of Acinetobacter baumannii, accounting for 48.4%. The drug resistance rates of Acinetobacter baumannii to most of the antimicrobial agents were more than 55%. Compound antibacterial is more effective than the single drug ingredient. Compared with other antimicrobial agents, β-lactams/β-lactamase inhibitor compound and carbapenems antimicrobial agents were more sensitive. Conclusion The drug resistance of Acinetobacter baumannii is serious and has differences among hospitals. Clinicians should monitor the drug resistance of Acinetobacter baumannii timely and choose proper antibiotics according to the results of drug sensitivity.

Citation： XUGui-ting, MIChen-rong, LIWen-hui, ZHANGYi-bo, GONGZheng-feng, NIYu-xing, WANGQun. Distribution and Drug Resistance of Acinetobacter baumannii Isolated from Inpatients in Ruijin Hospital from 2008 to 2012. West China Medical Journal, 2014, 29(3): 413-416. doi: 10.7507/1002-0179.20140125 Copy

1.	Peleg AY,Seifert H,Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen[J]. Clin Microbiol Rev,2008,21(3):538-582.
2.	熊麗蓉, 劉耀, 謝林利, 等. 我院2006-2011年鮑曼不動桿菌臨床分布及耐藥性分析[J]. 中國藥房, 2012, 23(46):4369-4370.
3.	徐惠, 馬智超, 羅明, 等. 某三甲綜合性醫院20年間出院患者年齡結構變遷[J]. 中國衛生統計, 2013, 30(5):758-759.
4.	劉德新, 盧俊英, 田加坤, 等. 綜合性ICU鮑曼不動桿菌肺部感染調查及耐藥性分析[J]. 中國實驗診斷學, 2013, 17(1):127-129.
5.	袁星, 沈繼錄, 徐元宏. 120株臨床分離鮑曼不動桿菌感染的分布和耐藥性分析[J]. 現代預防醫學, 2011(10):1901-1903, 1907.
6.	羅鵬, 戴瑋, 張莉萍. 1582株鮑曼不動桿菌的臨床分布及耐藥性分析[J]. 重慶醫學, 2011(3):224-225, 228.
7.	Dai TH, Huang YY, Sulbha KS, et al. Topical antimicrobials for burn wound infections[J]. Recent Pat Antiinfect Drug Discov, 2010, 5(2):124-151.
8.	汪復, 朱德妹, 胡付品, 等. 2008年中國CHINET細菌耐藥性監測[J]. 中國感染與化療雜志, 2009, 9(5):321-329.
9.	汪復, 朱德妹, 胡付品, 等. 2009年中國CHINET細菌耐藥性監測[J]. 中國感染與化療雜志, 2010, 10(5):325-334.
10.	朱德妹, 汪復, 胡付品, 等. 2010年中國CHINET細菌耐藥性監測[J]. 中國感染與化療雜志, 2011, 11(5):321-329.
11.	胡付品, 朱德妹, 汪復, 等. 2011年中國CHINET細菌耐藥性監測[J]. 中國感染與化療雜志, 2012(5):321-329.
12.	汪復, 朱德妹, 胡付品, 等. 2012年中國CHINET細菌耐藥性監測[J]. 中國感染與化療雜志, 2013, 13(5):321-330.
13.	談華, 邵海楓, 王錦娜, 等. 舒巴坦單劑及舒巴坦與第三代頭孢菌素聯合對鮑曼不動桿菌的體外抗菌作用比較[J]. 中國抗生素雜志, 2006, 31(8):488-491.
14.	Kiffer CR, Sampaio JL, Sinto S, et al. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii[J]. Diagn Microbiol Infect Dis, 2005, 52(4):317-322.
15.	李玉強, 萬忠林. 我院1999年1月-2011年9月鮑曼不動桿菌的分布及耐藥性分析[J]. 中國藥房, 2012(6):529-531.
16.	唐曉鈴, 楊縉. 重癥監護病房鮑曼不動桿菌感染現狀及耐藥性分析[J]. 重慶醫學, 2013, 42(3):302-303.
17.	李華, 申亞暉, 史躍杰. 重癥醫學科內感染患者病原菌的分布及鮑曼不動桿菌耐藥分析[J]. 中國全科醫學, 2012, 15(7):813-815.
18.	王輝, 郭萍, 孫宏莉, 等. 碳青霉烯類耐藥的不動桿菌分子流行病學及其泛耐藥的分子機制[J]. 中華檢驗醫學雜志, 2006(12):1066-1073.
19.	陳佰義, 何禮賢, 胡必杰, 等. 中國鮑曼不動桿菌感染診治與防控專家共識[J]. 中國醫藥科學, 2012, 92(8):3-8.

1. Peleg AY,Seifert H,Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen[J]. Clin Microbiol Rev,2008,21(3):538-582.
2. 熊麗蓉, 劉耀, 謝林利, 等. 我院2006-2011年鮑曼不動桿菌臨床分布及耐藥性分析[J]. 中國藥房, 2012, 23(46):4369-4370.
3. 徐惠, 馬智超, 羅明, 等. 某三甲綜合性醫院20年間出院患者年齡結構變遷[J]. 中國衛生統計, 2013, 30(5):758-759.
4. 劉德新, 盧俊英, 田加坤, 等. 綜合性ICU鮑曼不動桿菌肺部感染調查及耐藥性分析[J]. 中國實驗診斷學, 2013, 17(1):127-129.
5. 袁星, 沈繼錄, 徐元宏. 120株臨床分離鮑曼不動桿菌感染的分布和耐藥性分析[J]. 現代預防醫學, 2011(10):1901-1903, 1907.
6. 羅鵬, 戴瑋, 張莉萍. 1582株鮑曼不動桿菌的臨床分布及耐藥性分析[J]. 重慶醫學, 2011(3):224-225, 228.
7. Dai TH, Huang YY, Sulbha KS, et al. Topical antimicrobials for burn wound infections[J]. Recent Pat Antiinfect Drug Discov, 2010, 5(2):124-151.
8. 汪復, 朱德妹, 胡付品, 等. 2008年中國CHINET細菌耐藥性監測[J]. 中國感染與化療雜志, 2009, 9(5):321-329.
9. 汪復, 朱德妹, 胡付品, 等. 2009年中國CHINET細菌耐藥性監測[J]. 中國感染與化療雜志, 2010, 10(5):325-334.
10. 朱德妹, 汪復, 胡付品, 等. 2010年中國CHINET細菌耐藥性監測[J]. 中國感染與化療雜志, 2011, 11(5):321-329.
11. 胡付品, 朱德妹, 汪復, 等. 2011年中國CHINET細菌耐藥性監測[J]. 中國感染與化療雜志, 2012(5):321-329.
12. 汪復, 朱德妹, 胡付品, 等. 2012年中國CHINET細菌耐藥性監測[J]. 中國感染與化療雜志, 2013, 13(5):321-330.
13. 談華, 邵海楓, 王錦娜, 等. 舒巴坦單劑及舒巴坦與第三代頭孢菌素聯合對鮑曼不動桿菌的體外抗菌作用比較[J]. 中國抗生素雜志, 2006, 31(8):488-491.
14. Kiffer CR, Sampaio JL, Sinto S, et al. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii[J]. Diagn Microbiol Infect Dis, 2005, 52(4):317-322.
15. 李玉強, 萬忠林. 我院1999年1月-2011年9月鮑曼不動桿菌的分布及耐藥性分析[J]. 中國藥房, 2012(6):529-531.
16. 唐曉鈴, 楊縉. 重癥監護病房鮑曼不動桿菌感染現狀及耐藥性分析[J]. 重慶醫學, 2013, 42(3):302-303.
17. 李華, 申亞暉, 史躍杰. 重癥醫學科內感染患者病原菌的分布及鮑曼不動桿菌耐藥分析[J]. 中國全科醫學, 2012, 15(7):813-815.
18. 王輝, 郭萍, 孫宏莉, 等. 碳青霉烯類耐藥的不動桿菌分子流行病學及其泛耐藥的分子機制[J]. 中華檢驗醫學雜志, 2006(12):1066-1073.
19. 陳佰義, 何禮賢, 胡必杰, 等. 中國鮑曼不動桿菌感染診治與防控專家共識[J]. 中國醫藥科學, 2012, 92(8):3-8.

West China Medical Journal

Distribution and Drug Resistance of Acinetobacter baumannii Isolated from Inpatients in Ruijin Hospital from 2008 to 2012

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content